{"id":55032,"date":"2026-01-22T01:44:21","date_gmt":"2026-01-21T17:44:21","guid":{"rendered":"https:\/\/flcube.com\/?p=55032"},"modified":"2026-01-22T01:44:23","modified_gmt":"2026-01-21T17:44:23","slug":"kawin-technology-withdraws-hepatitis-b-filing-for-peginterferon-alfacon-2-after-nmpa-feedback","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55032","title":{"rendered":"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback"},"content":{"rendered":"\n<p><strong>Kawin Technology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688687:SHA\">SHA: 688687<\/a>) announced it has <strong>voluntarily withdrawn<\/strong> its market filing for <strong>peginterferon alfacon\u20112<\/strong> in combination with <strong>tenofovir alafenamide fumarate (TAF)<\/strong> for <strong>adult chronic hepatitis B (HBV)<\/strong>, following feedback from China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The company plans to conduct <strong>additional supplementary clinical studies<\/strong> and may <strong>resubmit based on future data<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-update\">Regulatory Update<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Kawin Technology (688687.SH)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Peginterferon alfacon\u20112 (long\u2011acting interferon)<\/td><\/tr><tr><td>**Original Indication<\/td><td>Chronic hepatitis C (HCV) \u2013 approved 2018<\/td><\/tr><tr><td>**Supplemental Indication<\/td><td>HBV (combined with TAF) \u2013 <strong>voluntarily withdrawn<\/strong><\/td><\/tr><tr><td><strong>Filing Submitted<\/strong><\/td><td>September\u202f2024<\/td><\/tr><tr><td><strong>Withdrawal Date<\/strong><\/td><td>15\u202fJan\u202f2026<\/td><\/tr><tr><td>**Reason<\/td><td><strong>NMPA feedback<\/strong> and internal review; need for additional data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-study-results-amp-significance\">Clinical Study Results &amp; Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>**Study Design<\/td><td>World\u2019s first 48\u2011week interferon + nucleoside analog registration study<\/td><\/tr><tr><td>**Primary Endpoint<\/td><td>Hepatitis B surface antigen (HBsAg) loss<\/td><\/tr><tr><td><strong>HBsAg &lt;10\u202fIU\/mL<\/strong><\/td><td><strong>&gt;50%<\/strong> of patients with low baseline HBsAg and interferon\u2011responsive profiles<\/td><\/tr><tr><td><strong>HBsAg Clearance<\/strong><\/td><td><strong>&gt;20%<\/strong> of patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Benefit:<\/strong> Demonstrated <strong>significant HBsAg reduction<\/strong> and clearance in <strong>advantaged patient populations<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First to evaluate long\u2011acting interferon + TAF regimen with <strong>HBsAg loss as primary endpoint<\/strong><\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> Results support potential <strong>functional cure pathway<\/strong>, but NMPA requires <strong>additional data<\/strong> for broader patient labeling<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China HBV Market<\/th><th>Global HBV Market<\/th><\/tr><\/thead><tbody><tr><td><strong>HBV Patients (2026E)<\/strong><\/td><td>87\u202fmillion<\/td><td>296\u202fmillion<\/td><\/tr><tr><td><strong>Functional Cure Rate (Current)<\/strong><\/td><td>&lt;5%<\/td><td>&lt;5%<\/td><\/tr><tr><td><strong>Interferon\u2011Based Therapy Share<\/strong><\/td><td>12%<\/td><td>8%<\/td><\/tr><tr><td><strong>Addressable Market (2030E)<\/strong><\/td><td>\u00a518\u202fbillion<\/td><td>$12\u202fbillion<\/td><\/tr><tr><td><strong>Kawin Peak Revenue (pre\u2011withdrawal)<\/strong><\/td><td>\u00a5420\u202fmillion<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pegasys<\/strong> (Roche) \u2013 Standard interferon for HBV, limited efficacy<\/li>\n\n\n\n<li><strong>Vemlidy<\/strong> (Gilead) \u2013 TAF monotherapy, no functional cure<\/li>\n\n\n\n<li><strong>Bepirovirsen<\/strong> (GSK) \u2013 RNA\u2011based functional cure candidate, Phase\u202fIII<\/li>\n\n\n\n<li><strong>Peginterferon alfacon\u20112<\/strong> \u2013 <strong>differentiated long\u2011acting interferon<\/strong> with <strong>potential functional cure<\/strong> if resubmitted successfully<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Kawin\u2019s <strong>Wuhan biologics facility<\/strong> (capacity 5\u202fmillion vials\/year) will continue producing peginterferon alfacon\u20112 for HCV; <strong>no capacity constraints<\/strong> for future HBV trials<\/li>\n\n\n\n<li><strong>Clinical Next Steps:<\/strong><\/li>\n\n\n\n<li><strong>Supplementary studies<\/strong> to <strong>broaden patient population<\/strong> beyond \u201cadvantaged\u201d subgroup<\/li>\n\n\n\n<li><strong>Potential resubmission timeline:<\/strong> <strong>H2\u202f2027<\/strong><\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> Withdrawal <strong>delays revenue<\/strong> by <strong>12\u201118 months<\/strong>, but <strong>preserves optionality<\/strong> for stronger label<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> HBV program complements Kawin\u2019s <strong>NASH<\/strong> and <strong>oncology interferon<\/strong> programs<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding supplementary clinical studies, potential resubmission timelines, and commercial forecasts for peginterferon alfacon\u20112. Actual results may differ due to competitive dynamics, regulatory requirements, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688687_20260121_BY07.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688687_20260121_BY07.\"><\/object><a id=\"wp-block-file--media-5f03d6c7-da2b-44d2-a2a6-15f9bbaf9168\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688687_20260121_BY07.pdf\">688687_20260121_BY07<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688687_20260121_BY07.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5f03d6c7-da2b-44d2-a2a6-15f9bbaf9168\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4567,4566,89],"class_list":["post-55032","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-kawin-technology","tag-sha-688687","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112 in combination with tenofovir alafenamide fumarate (TAF) for adult chronic hepatitis B (HBV), following feedback from China\u2019s National Medical Products Administration (NMPA). The company plans to conduct additional supplementary clinical studies and may resubmit based on future data.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55032\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback\" \/>\n<meta property=\"og:description\" content=\"Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112 in combination with tenofovir alafenamide fumarate (TAF) for adult chronic hepatitis B (HBV), following feedback from China\u2019s National Medical Products Administration (NMPA). The company plans to conduct additional supplementary clinical studies and may resubmit based on future data.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55032\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-21T17:44:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-21T17:44:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55032#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55032\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback\",\"datePublished\":\"2026-01-21T17:44:21+00:00\",\"dateModified\":\"2026-01-21T17:44:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55032\"},\"wordCount\":386,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Kawin Technology\",\"SHA: 688687\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55032#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55032\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55032\",\"name\":\"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-21T17:44:21+00:00\",\"dateModified\":\"2026-01-21T17:44:23+00:00\",\"description\":\"Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112 in combination with tenofovir alafenamide fumarate (TAF) for adult chronic hepatitis B (HBV), following feedback from China\u2019s National Medical Products Administration (NMPA). The company plans to conduct additional supplementary clinical studies and may resubmit based on future data.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55032#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55032\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55032#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback - Insight, China&#039;s Pharmaceutical Industry","description":"Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112 in combination with tenofovir alafenamide fumarate (TAF) for adult chronic hepatitis B (HBV), following feedback from China\u2019s National Medical Products Administration (NMPA). The company plans to conduct additional supplementary clinical studies and may resubmit based on future data.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55032","og_locale":"en_US","og_type":"article","og_title":"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback","og_description":"Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112 in combination with tenofovir alafenamide fumarate (TAF) for adult chronic hepatitis B (HBV), following feedback from China\u2019s National Medical Products Administration (NMPA). The company plans to conduct additional supplementary clinical studies and may resubmit based on future data.","og_url":"https:\/\/flcube.com\/?p=55032","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-21T17:44:21+00:00","article_modified_time":"2026-01-21T17:44:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55032#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55032"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback","datePublished":"2026-01-21T17:44:21+00:00","dateModified":"2026-01-21T17:44:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55032"},"wordCount":386,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Kawin Technology","SHA: 688687","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55032#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55032","url":"https:\/\/flcube.com\/?p=55032","name":"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-21T17:44:21+00:00","dateModified":"2026-01-21T17:44:23+00:00","description":"Kawin Technology (SHA: 688687) announced it has voluntarily withdrawn its market filing for peginterferon alfacon\u20112 in combination with tenofovir alafenamide fumarate (TAF) for adult chronic hepatitis B (HBV), following feedback from China\u2019s National Medical Products Administration (NMPA). The company plans to conduct additional supplementary clinical studies and may resubmit based on future data.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55032#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55032"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55032#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon\u20112 After NMPA Feedback"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55032"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55032\/revisions"}],"predecessor-version":[{"id":55035,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55032\/revisions\/55035"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}